Human medicines European public assessment report (EPAR): Lumykras, sotorasib, Carcinoma, Non-Small-Cell Lung, Date of authorisation: 06/01/2022, Revision: 2, Status: Authorised

Committee for Medicinal Products for Veterinary Use (CVMP): 3-5 October 2023, European Medicines Agency, Amsterdam, the Netherlands, from 03/10/2023 to 05/10/2023

CVMP: Agendas, minutes and reports

Agenda - Strengthening life-sciences innovation across Europe: EU-Innovation Network conference

Human medicines European public assessment report (EPAR): Glivec, imatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma;Gastrointestinal Stromal Tumors;Dermatofibrosarcoma;Myelodysplastic-Myeloproliferative Diseases;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Hypereosinophilic Syndrome, Date of authorisation: 07/11/2001, Revision: 46, Status: Authorised

Human medicines European public assessment report (EPAR): Briviact (in Italy: Nubriveo), brivaracetam, Epilepsy, Date of authorisation: 13/01/2016, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Tecentriq, atezolizumab, Carcinoma, Transitional Cell;Carcinoma, Non-Small-Cell Lung;Urologic Neoplasms;Breast Neoplasms;Small Cell Lung Carcinoma, Date of authorisation: 20/09/2017, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Artesunate Amivas, artesunate, Malaria, Date of authorisation: 22/11/2021, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Vargatef, nintedanib, Carcinoma, Non-Small-Cell Lung, Date of authorisation: 21/11/2014, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Simponi, golimumab, Arthritis, Psoriatic;Spondylitis, Ankylosing;Colitis, Ulcerative;Arthritis, Rheumatoid, Date of authorisation: 01/10/2009, Revision: 48, Status: Authorised